首页> 外文期刊>Experimental and clinical transplantation >Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk
【24h】

Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk

机译:兔抗胸腺细胞球蛋白理想剂量与总剂量对高免疫风险肾脏移植患者结局的影响

获取原文
       

摘要

Objectives: The optimal dose of rabbit antithymocyte globulin induction therapy in kidney transplant recipients with high immunologic risk lacks consensus. The purpose of this study was to evaluate the effect of using ideal body weight rather than total body weight for the weight-based dose calculations in this patient population. Materials and Methods: Data were retrospectively collected on 89 adult patients who received rabbit antithymocyte globulin induction therapy for high immunologic risk kidney transplant. Hospital protocol changed from the use of cumulative rabbit antithymocyte globulin doses of 7.5 mg/kg total body weight to 7.5 mg/kg ideal body weight in 2009. Patients were separated into 2 cohorts based on the amount of rabbit antithymocyte globulin (in mg/kg total body weight) received. Rate of biopsy-proven acute rejection, patient survival, and allograft function were evaluated at 90 days and 1 year after transplant. Cost of induction therapy was also evaluated. Results: Baseline demographics were predominantly similar between the 2 cohorts. No significant dif-ference in maintenance immunosuppression was identified. Rates of biopsy-proven acute rejection at 90 days and 1 year were similar between ideal and total body weight cohorts (4.2% vs 0% at 90 days, P = .5; 8.7% vs 0% at 1 year, P = .13). Patient survival and allograft function were also similar. Median cost of rabbit antithymocyte globulin induction therapy per patient was lower in the ideal body weight cohort, but this difference was not statistically significant ($17 542 vs $19 934; P = .3). Conclusions: Our results suggest that use of ideal body weight for dose calculations of rabbit antithymocyte globulin induction therapy in high immunologic risk kidney transplant recipients at 7.5 mg/kg results in low rates of acute rejection with a safety profile similar to that shown with a total body weight dosage. Use of ideal body weight for lower cumulative doses may still need further evaluation in this patient population.
机译:目的:在免疫风险较高的肾脏移植受者中,兔抗胸腺细胞球蛋白诱导疗法的最佳剂量尚无共识。这项研究的目的是评估在该患者人群中使用理想体重而不是总体重进行基于体重的剂量计算的效果。资料与方法:回顾性收集89例接受兔抗胸腺细胞球蛋白诱导疗法用于高免疫风险肾脏移植的成年患者的数据。医院方案从使用累积的兔抗胸腺细胞球蛋白总剂量7.5 mg / kg更改为2009年的7.5 mg / kg理想体重。根据兔抗胸腺细胞球蛋白的量(以mg / kg为单位)将患者分为2组总体重)。在移植后90天和1年,评估经活检证实的急性排斥反应,患者存活率和同种异体移植功能的发生率。还评估了诱导治疗的费用。结果:2个队列之间的基线人口统计学主要相似。在维持免疫抑制方面未发现明显差异。理想组和总体重组在90天和1年时经活检证实的急性排斥反应的发生率相似(90天时为4.2%vs 0%,P = 0.5; 1年时为8.7%vs 0%,P = 0.13) )。患者存活率和同种异体移植功能也相似。在理想的体重队列中,每位患者接受兔抗胸腺细胞球蛋白诱导疗法的中位费用较低,但这一差异无统计学意义($ 17 542 vs $ 19 934; P = .3)。结论:我们的结果表明,在高免疫风险肾脏移植受者中以7.5毫克/千克的理想体重用于兔抗胸腺细胞球蛋白诱导疗法的剂量计算会导致急性排斥反应发生率低,其安全性与总剂量相似体重剂量。对于较低的累积剂量使用理想体重可能仍需要对该患者人群进行进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号